Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026GlobeNewsWire · Oct 15, 2026
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving Average – Here’s WhyDefense World · Oct 8, 2026
Seres Therapeutics (NASDAQ:MCRB) Share Price Breaks Below 50 Day Moving Average – Should You Sell?Defense World · Sep 30, 2026
Seres Therapeutics (NASDAQ:MCRB) and Celldex Therapeutics (NASDAQ:CLDX) Head to Head ReviewDefense World · Sep 16, 2026
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Sep 8, 2026
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 1, 2026Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$2.18 | $0.47 | Beat |
| May 5, 2026 | -$1.88 | -$2.08 | Miss |
| Mar 12, 2026 | -$2.39 | -$1.78 | Beat |
| Nov 5, 2025 | $0.05 | $0.94 | Beat |
| Aug 6, 2025 | -$2.72 | -$2.27 | Beat |
| May 7, 2025 | -$0.67 | -$3.75 | Miss |